Overcoming these odds, Serum launched its first therapeutic antitetanus serum within two years, then began producing the antitetanus vaccines.

FORBES: Magazine Article

Serum expects its own boost from finally entering regulated markets like the U.S. and Europe, where prices are 10 to 20 times higher.

FORBES: Magazine Article

Thanks mainly to low overhead, tight cost controls and mass production, the company was able to keep Serum's vaccines priced lower than its competitors'.

FORBES: Horse Sense

In 2001, Serum Institute decided to venture out of its traditional childhood vaccines with known technology and develop a new vaccine of great need in sub-Saharan Africa.

FORBES: Corporate Entrepreneurship: Eliminating Disease via Public-Private Partnerships

Not that it will be easy for Serum, which will need USFDA approval for its products, involving drawn-out and costly human clinical trials.

FORBES: On The Cover/Top Stories

It has had a relationship with Akorn for three years to market injectable anticancer products and rabies monoclonal antibodies manufactured by Serum, and recently announced it was buying 2 million shares in its American partner.

FORBES: Magazine Article